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Background/Aims: In oncology, new combined treatments make it difficult to
order dose levels according to monotonically increasing toxicity. New flexible
dose-finding designs that take into account uncertainty in dose levels ordering were
compared to classical designs through simulations in the setting of the monotonicity
assumption violation. We give recommendations for the choice of dose-finding design.
Methods: Motivated by a clinical trial for patients with high-risk neuroblastoma, we
considered designs that require a monotonicity assumption, the Bayesian Continual
Reassessment Method, the modified Toxicity Probability Interval, the Bayesian Optimal
Interval design, and designs that relax monotonicity assumption, the Bayesian Partial
Ordering Continual Reassessment Method and the No Monotonicity Assumption design.
We considered 15 scenarios including monotonic and non-monotonic dose-toxicity
relationships among 6 dose levels.
Results: The No Monotonicity Assumption and Partial Ordering Continual
Reassessment Method designs were robust to the violation of the monotonicity
assumption. Under non-monotonic scenarios, the No Monotonicity Assumption design
selected the correct dose level more often than alternative methods on average. Under
the majority of monotonic scenarios, the Partial Ordering Continual Reassessment
Method selected the correct dose level more often than the No Monotonicity Assumption
design. Other designs were impacted by the violation of the monotonicity assumption
with a proportion of correct selections below 20% in most scenarios. Under monotonic
scenarios, the highest proportions of correct selections were achieved using the Continual
Reassessment Method and the Bayesian Optimal Interval design (between 52.8% to
73.1%). The costs of relaxing the monotonicity assumption by the No Monotonicity
Assumption design and Partial Ordering Continual Reassessment Method were decreases
in the proportions of correct selections under monotonic scenarios ranging from 5.3% to
20.7% and from 1.4% to 16.1%, respectively compared to the best performing design and
were higher proportions of patients allocated to toxic dose levels during the trial.
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Conclusions: Innovative oncology treatments may no longer follow monotonic dose levels
ordering which makes standard phase I methods fail. In such a setting, appropriate
designs, as the No Monotonicity Assumption or Partial Ordering Continual Reassessment
Method designs, should be used to safely determine recommended for phase II dose.




The main objective of phase I clinical trials is to identify the maximum
tolerated dose (MTD). The MTD is defined as the highest dose that can be
administrated, targeting an acceptable rate of toxicity defined as dose-limiting
toxicities (DLT). A number of study designs has been proposed to identify the
MTD in single agent trials: algorithm-based, e.g. the 3+3 method1,
model-based e.g. the Continual Reassessment Method2, and model-assisted
designs, e.g. the Toxicity Probability Interval method3 or the Bayesian
Optimal Interval designs4. The common feature of these methods is the
assumption of a monotonic relationship between toxicity and dose that holds
in single-agent trials.5 However, it becomes more common in oncology to
combine targeted treatments with established cytotoxic chemotherapy
regimens.6 In case of a synergistic interaction between two treatments,
non-monotonic shapes, namely a plateau or a bi-modal relationship, can be
expected.7
An example is the SIOPEN’s clinical trial in high-risk neuroblastoma which
motivated this work. Neuroblastoma is the most frequent individual type of
solid tumour in children.8 Pre-clinical data suggests that the use of
immunotherapy (the dinutuximab beta targeting the disialoganglioside GD2)
in combination with a conventional chemotherapy can improve the induction
treatment.9;10;11 The SIOPEN clinical trial will assess the toxicity of
dinutuximab combined with the induction chemotherapy under different
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schedules. The combination of dinutuximab with this chemotherapy regimen
varies depending on the dose of dinutuximab and also on the schedule of
administration (see Figure 1). In the following, a dose level refers to a
combination of immunotherapy dose and extent of co-administration with
chemotherapy. The starting dose level corresponds to a sequential
administration of chemotherapy and dinutuximab with no overlapping
administration: standard chemotherapy regimen drugs (cisplatin and
etoposide) are given from day 1 to 4 and dinutuximab is started on day 5.
The dose escalation is designed to reach the highest dose of immunotherapy
and a concomitant administration of immunotherapy and chemotherapy, dose
level 5 and 6.
The main challenge of this trial is that not all dose levels can be ordered
according to a monotonically increasing toxicity. Specifically, it is unknown
whether dose levels 3 and 4 are more or less toxic than dose levels 4 and 5,
respectively. Thus, the monotonicity assumption upon which standard
single-agent dose-finding designs are based is violated, and corresponding
methods cannot be efficiently applied. Furthermore, the combination space in
this example, while partially ordered, is not a matrix of combination
comprised of discrete levels of two agents that is the framework, for which
many existing combination methods are developed for.12 As a result, these
methods cannot be applied to conduct dose-finding in the motivating
example. Others approaches considering the related schedule-finding problem
have been published. Braun et al.13 proposed a design to find the best
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dose level 1 22,5 
                        
    
                        
dose level 2 50 
                        
    
                        
dose level 3 50 
                        
    
                        
dose level 4 70 
                        
    
                        
dose level 5 70 
                        
    
                        
dose level 6 87,5 
                        
                              day with dinutuximab infusion
*Cisplatin (from day1 to day4) and etoposide (from day1 to day3) are given at the same dose at all dose levels. 
Figure 1: Dose levels for the combination trial of dinutuximab and chemotherapy course
(P/E).
’Maximum Tolerated Schedule’. In this design, the main concern is delayed
toxicity occurring after repeated treatment administrations. Thus, the
primary endpoint is the time to toxicity. This is of interest for applications
where toxicity is expected after the first administration. In our setting,
toxicity is expected in the first cycle. Thall et al.14 proposed an extension of
the method by Braun et al.13 to jointly optimize dose and schedule in a two
step procedure. Guo and Yuan15 also proposed a design based on a Bayesian
dynamic model that jointly optimizes dose and schedule for toxicity and
efficacy. These dose-schedule designs assume that “the duration of therapy
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increases” and do not straightforwardly allow for the incorporation of the
uncertainty in the toxicity ordering between “dose levels”. For example, in
their approach, of Guo and Yuan assume that the mean toxicity probability
can be written as the function of difference in two doses. In our example,
however, it remains unclear what the distance between two doses would be as
the “dose-levels” are “combination of two treatments given at different doses”.
Furthermore, in the motivating setting, one needs to deal with the effect
arising from the therapies given sequentially or with overlapping (for various
number of days) that complicates the problem further. Therefore, we did not
include these methods in our comparison. Instead, two recently proposed
dose-finding designs, the model-based Partial Ordering Continual
Reassessment Method by Wages et al.16, and the model-free “No
Monotonicity Assumption” design by Mozgunov and Jaki17, are flexible
enough to be applied to the motivating trial directly.
The aim of our study is to investigate the performance of several Phase I
dose-finding designs in the setting of the monotonicity assumption violation.
Specifically, we aim to investigate the consequences of applying designs based
on the monotonicity to such settings, and to study how well the alternative
designs overcome the uncertainty about the ordering. While several
comparison of dose-finding designs have been proposed in the literature
18;19;20;21, they primarily concern settings with a known monotonicity ordering,
or specific combination settings (see e.g. Riviere et al.12); the comparison
studies in settings similar to the motivating trial are still sparse to date.
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This article is structured as follows. In the methods section, we introduce the
designs that relax monotonicity assumption and their statistical principles. In
the results section, we specify the simulation settings, the elicitation of
optimal parameters for each design and provide operating characteristics in
the scenarios inspired by the motivating example. We conclude with practical
recommendations and discussion in the discussion section.
8
Methods
Consider a clinical trial in which M dose levels x1, . . . , xM are studied and N
patients are available in the trial. Let Y be a binary random variable, where
yi = 1 denotes the observation of a DLT for patient i. The DLT probability
given xm is denoted by pm = P(Y = 1|xm), m = 1, . . . ,M . The goal of the
trial is to find the MTD xT such that P(Y = 1|x = xT ) = γ where γ is the
targeted rate of toxicity.
Below, we recall dose finding designs that relax the monotonicity assumption,
the Partial Ordering Continual Reassessment Method and the No
Monotonicity Assumption design. We refer the reader to O’Quigley et al.2 for
the details of the Continual Reassessment Method, to Ji et al.3 for the details
of the Toxicity Probability Interval method, and to Liu and Yuan4 for the
details of the Bayesian Optimal Interval design.
Partial ordering continual reassessment method
Consider a trial, in which at least two dose levels can not be ordered. Conaway
et al.22 proposed a framework of partial order restrictions in order to provide
efficient toxicity estimations. Wages et al.16 extended this approach using a
working parametric model, such as proposed in O’Quigley et al.2. Let us assume
that S monotonic orderings are considered as clinically plausible. For ordering s,
DLT probabilities are assumed to have a parametric form pm = ψs(αm, θ) where
αm is the standardized level for dose m and θ is the working model’s unknown
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parameter. Denote the prior distribution of θ by f0 and let ri ∈ {x1, . . . , xM}
be the dose level recommended for the patient i. Then, as toxicity data for n






φs(ri, yi, θ) = ψs(ri, θ)
yi(1− ψs(ri, θ))1−yi. (1)
The posterior distribution for parameter θ under ordering s can be computed




i=1 φs(ri, yi, θ)∫
R f0(u)
∏n
i=1 φs(ri, yi, u)du
. (2)
In total, S dose-toxicity models are fitted. Given the prior distribution of
orderings qs = {q1, . . . , qS}, the posterior probability of ordering s after n




RLs,n(u|y1, . . . , yn)f0(u)du∑S
s=1 qs
∫
RLs,n(u|y1, . . . , yn)f0(u)du
. (3)
The next group of patients is allocated based on ordering s∗ corresponding to
the maximum of pin,s, s = 1, . . . , S. For ordering s
∗, let θˆs∗,n be the
corresponding posterior mean. Using the “plug-in” estimate for the DLT
probability pˆm,n = ψ
∗
s(αs∗, θˆs∗), we assign the next group of patients to the
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dose level rn+1 minimizing for all m
rn+1 = min
m
(|pˆm,n − γ|) (4)
The design proceeds until the maximum number of patientsN have been treated
or if the following safety constraint
P (ψ(α1, θ) > γ) > ξ (5)
is violated, where ξ is a probability controlling overdosing, and the left-hand
side is found with respect to the posterior density.
The Partial Ordering Continual Reassessment Method design is a
model-based design and relies on a particular working model and pre-specified
set of S ordering. One can benefit from using model-free designs in a setting
with unexpected dose-toxicity shapes or in case of a large number of possible
orderings.
No Monotonicity Assumption design
As an alternative to model-based designs, Mozgunov and Jaki17 proposed an
information-theoretic approach to dose-finding trials that does not require any
parametric or monotonicity assumption. We will refer to this design as to a “No
Monotonicity Assumption” design. This approach models DLT probabilities for
11




for the dose-escalation. The No Monotonicity Assumption design does not
imply a monotonicity assumption in the decision rules. It was found that due
to special properties of (6), the correct MTD selection can be achieved
without monotonicity assumption. We extend the estimator used by
Mozgunov and Jaki17;23 to decrease the contribution of the prior information
faster and proportionally to nm. The estimate of pm, after observing tm DLT








where λ is the down-weighting parameter and βm, νm > 0 are sets of
parameters of the prior Beta distribution B(νm + 1, βm − νm + 1) of
probability pm.
The first allocation is based on prior information νm, βm, only. Assume that
nm patients were assigned to each dose levels and tm DLT were observed,
respectively. The next cohort of patients will be assigned to dose level x∗m for
which the criterion (6) is minimized. The design proceeds until the total
number of patient N is reached or a safety constraint is violated. The No
Monotonicity Assumption design uses a time-varying safety constraint17;23.
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The dose level xm is unsafe if after nm patients accrued at this dose level
∫ 1
γ
fnm(p)dp ≥ ξnm = max(1− knm, ξfinal) (7)
where ξnm is the overdosing probability, fnm is the Beta posterior, k the rate
of the safety constraint strictness and ξfinal the final level of confidence. The
increasing overdosing probability implies that the safety constraint becomes
stricter as the trial goes. Similarly, the No Monotonicity Assumption design
includes a futility constraint to avoid patient allocation to dose level below the
MTD. Dose level xm is futile if after nm patients
∫ 1
γ′
fnm(p)dp ≤ ζ (8)
where γ′ is the futility bound and ζ the controlling probability. Parameters of
both safety and futility constraint should be calibrated over scenarios of
interest using information about partial ordering. The No Monotonicity
Assumption design incorporates the information about monotonicity between
any pair of dose levels by restrictions known as the coherent
escalation/de-escalation principles 24 formulated as follows:
• Coherent escalation: if at least one DLT was observed given a current dose
level for a previous cohort, more toxic dose levels (with respect to a partial
monotonic ordering) cannot be selected for next patient.
• Coherent de-escalation: if no DLT outcomes were observed for a previous
cohort given the current dose level then less toxic dose cannot be selected
for the next cohort.
13




To compare the operating characteristics of the dose-finding designs, we
consider a simulation study in the setting of (partially) unknown ordering of
dose levels. The SIOPEN’s clinical trial for patients with high risk
neuroblastoma which motivated this work, was a first step to improve the
induction treatment9;10;11, i.e. the first part of the treatment aiming to reduce
the tumor burden in order to facilitate surgery and subsequent treatments.
Different chemotherapy regimens have been evaluated with increasing
intensities of conventional chemotherapies over the last four decades25;26. The
SIOPEN’s clinical trial will assess the toxicity of a combined treatment. We
considered six dose levels combining immunotherapy and chemotherapy using
different schedules with n = 30 patients. Based on past experience, the
expected accrual rate is 4 patients by month and the toxicity is evaluated after
3 weeks, so we considered the inclusion of 3 patients cohorts in this trial. The
goal was to find the MTD corresponding to the dose level with the toxicity
probability closest to the target value of γ = 0.30. We considered a trial with
one de-escalation dose level (d1), a starting dose level (d2) and four escalation
dose levels (d3 – d6). The main challenge was that the administration of the
drugs in combination (either simultaneously or sequentially) could have a
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significant impact on the toxicity. A clinician could not put in a monotonic
order dose levels d3, d4 and d4, d5. This resulted in two partial orderings
(partial in the sense that we can only order 5 out of 6 dose levels):
d1 < d2 < d3 < d5 < d6 (9)
and
d1 < d2 < d4 < d5 < d6 (10)
These two orderings were studied by various scenarios given in Figure 2.
Scenarios 1 and 2 corresponded to cases of excessive toxicity with the MTD




































































































































































































































Figure 2: Considered dose-toxicity shapes. The MTD is marked by a triangle and the dashed
horizontal line corresponds to the target DLT rate γ = 0.3.
being d1 and d2, respectively. For instance, scenario 1 accounted for the case
in which an unexpected mechanism of toxicity occurred and the starting dose
15
level toxicity was higher than expected by a clinician. These scenarios would
reveal the ability of the designs to avoid allocation to too toxic dose levels and
recommend the MTD at the beginning of the dose-escalation. For scenarios 3,
all possible permutation of the orderings due to unknown order of d3, d4 and
d4, d5 were considered. The scenario 3.1 was a monotonic scenario with the
MTD being d4. Scenarios 3.2 and 3.3 accounted for cases where orders of
d3, d4 and d4, d5 were inverted, with the MTD being d3 and d5 respectively.
The non-monotonic order resulted in a non-trivial shape of the dose-toxicity
relation. Scenarios 4 and 5 corresponded to flat dose-toxicity relations and
were included to investigate the ability of the designs to escalate quickly and
avoid patient’s allocation to sub-therapeutic doses. Scenario 5 corresponded
to the case of under dosing at all dose levels. Scenario 6, in which all doses
were toxic, evaluated the capacity of the safety constraints to avoid an
unethical recommendation to a toxic dose and an early stopping of study.
Scenarios 7-9 corresponded to cases where none of the dose levels matches
exactly the target toxicity probability of 0.30. These scenarios were chosen to
check the designs trend to select overdosing or underdosing levels. Note that
the permutation of dose levels d3, d4 and d4, d5 that did not change the MTD
location are not included in those scenarios.
In the simulation study, we focused on (i) the proportion of dose level
selection, (ii) the average number of patients assigned to each dose level, (iii)
the proportion of early stopping due to excessive toxicity, (iv) the probability
of selecting toxic dose levels as the MTD, (v) the percentage of patients
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assigned to toxic dose levels (above the MTD). Before the analysis, each of the
four designs were calibrated according to the stated trial setting.
Designs specification
For methods, which require parameters calibration, the “operational prior”
(the prior working uniformly well in many different scenarios) were specified
as follows.
For the Continual Reassessment Method and the Partial Ordering Continual
Reassessment Method simulations, the working model for dose-toxicity was the
one-parameter power model. For both methods, the following standardized
values were used:
(0.20, 0.30, 0.40, 0.50, 0.59, 0.67)
These values were obtained using using the getprior function from dfcrm
package27 using a half width of 0.05, a target toxicity of γ = 0.30, and the
prior MTD being the dose level 2. Sensitivity analyses showed that a half
width of 0.05 provided better operating characteristics than other values (see
Supplemental Materials for more details, considered values were 0.04, 0.06,
0.08 and 0.10). The least informative normal prior according to the algorithm
by Cheung28, θ ∼ N (0, 0.752) was used for both Continual Reassessment
Method and Partial Ordering Continual Reassessment Method. Overdosing
probability ξ = 0.80 was used for the safety constraint (5). In addition, the
Partial Ordering Continual Reassessment Method required orderings to be
specified. Using partial orderings 9 and 10, there were three feasible orderings
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in this setting
d1 < d2 < d3 < d4 < d5 < d6
d1 < d2 < d4 < d3 < d5 < d6
d1 < d2 < d3 < d5 < d4 < d6
These three orderings were included in the Partial Ordering Continual
Reassessment Method design and a clinician considered that all of them were
equally possible a-priori q1 = q2 = q3 = 1/3.
The Toxicity Probability Interval method requires specification of an
equivalence interval according to a physician’s advice. Following the
motivating example the parameters 1 = 2 = 0.10 were chosen. For others
parameters, the dose level 2 was used as the prior MTD and the cutoff
probability for excessive toxicity was ξ = 0.90
The Bayesian Optimal Interval design required specification of an
optimization interval, we used default values (0.18 - 0.42) as recommended by
Liu and Yuan4. For sake of comparability, the stopping rule based on the
cumulative number of patients treated at the same dose was not used. The
safety parameters of the Bayesian Optimal Interval design proposed in the
original work were used: the elimination dose threshold, pE = 0.95, and the
early stopping rule, δ = 0.05. The use of the early stopping rule, as explained
by Zhou et al.29, was motivated by the fact that investigators emphasized the
importance of conducting the motivating trial as safely as possible. The
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operating characteristics of the Bayesian Optimal Interval design without
using the early stopping rule can be found in Supplementary Materials.
The No Monotonicity Assumption design requires vectors ν = [ν1, . . . , νm]
T and
β = [β1, . . . , βm]
T to be specified prior to the trial. For the prior information
strength, β = 1 was chosen to emphasize a limited amount of information
available about dose levels. Then, ν represents prior mode probabilities for all
treatment levels (as standardized values above). These values were calibrated
as described by Mozgunov and Jaki17 over the considered set of scenarios. The
operational prior used in the simulations was
ν = [0.20, 0.23, 0.26, 0.29, 0.32, 0.35]T
This prior reflected the clinician elicitation that dose levels were in monotonic
order. Note, that this ordering could change as the trial progresses in contrast
to other methods. The prior probabilities were chosen to be close to each
other to ensure that all dose levels could be tested if data suggested so. For
the parameter of down-weighting λ = 0.25 was chosen. The coherent
escalation/de-escalation principles were applied with respect to the partial
orderings (9) and (10). Parameters of safety (7) and futility (8) constraints
were tuned over all scenarios and k = 0.005, ξfinal = 0.9, γ
′ = 0.25, ζ = 0.3
were fixed for this simulation study.
The optimal non-parametric benchmark design30;31 was included to get an
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optimal design reference.
For each scenario, 10 000 simulations were run using R32. The R code
underlying the simulations is available on GitHub at
(https://github.com/dose-finding/comparison-non-mono).
Operating characteristics
Operating characteristics for all considered designs are given in Tables 1-4.
They present the proportion of each dose selections with proportion of correct
selections in bold, the average number of patients assigned to each dose level
and several safety metrics: the proportion of early stopping due to safety
(Stop), the probability of selecting toxic doses as the MTD (SelTox) and the
average proportion of patients assigned to toxic doses above the MTD
(%Tox). Note that for scenarios where no dose levels met the target toxicity
probability, given in Tables 3 - 4, the dose level with true toxicity rate just
below the target was considered correct.
We start from considering the proportion of correct selections in scenarios
where the monotonicity assumption holds. The benefits of using a parametric
model were shown in monotonic scenarios as the Continual Reassessment
Method had the highest proportion of correct selections in scenario 2 (53.7%),
scenario 3.1 (52%); the Toxicity Probability Interval method had the highest
proportion of correct selections in scenario 1 (65.4%) and the Bayesian
Optimal Interval design had the highest proportion of correct selections in
scenario 4 (55.8%). The Bayesian Optimal Interval design also showed the
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highest proportion of correct selections in scenarios where no dose level
exactly matches the target toxicity probability: scenario 7.1, 8.1 and 9.1 with
73.1%, 61.1% and 60.8% respectively. The designs relaxing the monotonicity
assumption, No Monotonicity Assumption and Partial Ordering Continual
Reassessment Method, can lead to lower proportion of correct selections in the
monotonic scenarios. For instance, in scenario 3.1, No Monotonicity
Assumption and Partial Ordering Continual Reassessment Method had 40.0%
and 40.7% proportion of correct selections, nearly a 13% decrease compared to
Continual Reassessment Method. The differences were larger in scenarios
where no dose level exactly matches the target toxicity level, for example,
scenario 9.1 where the No Monotonicity Assumption design had a lower
proportion of correct selections by 21% compared to the Bayesian Optimal
Interval design.
Considering the proportion of correct selections in scenarios where the
monotonicity assumption was violated, the No Monotonicity Assumption
design showed the highest proportion of correct selections in most scenarios
with, for instance, 65% and 53.9% in scenarios 7.2 and 8.3. The Partial
Ordering Continual Reassessment Method showed the second highest
proportion of correct selections, after the No Monotonicity Assumption
design, in all non-monotonic scenarios with an exception in scenario 3.2, in
which Partial Ordering Continual Reassessment Method had the highest
proportion of correct selections of 44.7% against 38.5% for the No
Monotonicity Assumption design. The violation of the monotonicity
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assumption impacted the proportion of correct selections of the Bayesian
Optimal Interval design, Toxicity Probability Interval method and Continual
Reassessment Method design with proportions below 20% in the majority of
non-monotonic scenarios. In scenario 3.2, the Continual Reassessment Method
and Bayesian Optimal Interval design had 33.5% and 27.0% proportion of
correct selections, respectively, but they were still below the No Monotonicity
Assumption design and the Partial Ordering Continual Reassessment Method,
which had respectively 38.5% and 44.7%.
Investigating safety, the Continual Reassessment Method, the Partial
Ordering Continual Reassessment Method, the Bayesian Optimal Interval
design and the Toxicity Probability Interval method were able to terminate a
trial earlier for safety requirements in the highly toxic scenario 6 in nearly
90% of trials. The No Monotonicity Assumption design allowed early
terminations in 86.7% of simulated trials in scenario 6. The proportion of
early stopping for safety in scenario 1 exceeded 20% for the Bayesian Optimal
Interval design, the Continual Reassessment Method and the Partial Ordering
Continual Reassessment Method designs. In all other scenarios, all designs
had a probability of stopping close to 0. Considering the probability of
selecting a toxic dose in monotonic scenarios, the Toxicity Probability Interval
method had the lowest probability in all scenarios.
In monotonic scenarios, the Partial Ordering Continual Reassessment Method
had a higher probability to select toxic dose in scenarios 8.1 and 9.1 while
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performing similarly to No Monotonicity Assumption design under the rest of
monotonic scenarios. Considering the probability of selecting a toxic dose in
non-monotonic scenarios, the Toxicity Probability Interval method was still
the safest design. The Continual Reassessment Method showed the highest
probability of selecting a toxic dose in all non-monotonic scenarios with, for
instance, 52.5% in scenario 7.2. Comparing designs relaxing the monotonicity
assumption, the No Monotonicity Assumption design had the same or lower
probability of selecting a toxic dose than the Partial Ordering Continual
Reassessment Method under twelve scenarios, with a reduction of up to 6.5%
in scenario 6. Under scenarios 3.2, 6 and 7.1, the No Monotonicity
Assumption design resulted in higher proportions of toxic dose
recommendations than the Partial Ordering Continual Reassessment Method
with differences between 1.4% to 5.7%.
Concerning the percentage of patients assigned to toxic dose levels under
monotonic scenarios, the designs relaxing monotonicity, Partial Ordering
Continual Reassessment Method and No Monotonicity Assumption design,
resulted in more patients receiving toxic doses compared to the rest of the
designs, especially in scenario 2 with 35.6% and 41.5% of patients assigned to
toxic dose levels, respectively compared to 26% for the Toxicity Probability
Interval method corresponding to the least proportion of patients allocated to
toxic doses. Under non-monotonic scenarios however, all designs showed
comparable percentage of assignment to toxic doses except for the
conservative Toxicity Probability Interval method. Comparing the designs
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relaxing monotonicity, the No Monotonicity Assumption design assigned more
patients to toxic doses than the Partial Ordering Continual Reassessment
Method under scenarios 3.2 and 8.2 where the dose level after the MTD drop
below the target DLT rate. The largest difference was in scenario 3.2 where
the Partial Ordering Continual Reassessment Method assigned 15.4% versus
25.3% patients on toxic doses for the No Monotonicity Assumption design.
Both designs had comparable assignment to toxic doses in other
non-monotonic scenarios.
Discussion and recommendations
In this work, we have considered the setting, in which neither single agent nor
the majority of combination dose-finding methods can be directly applied.
This motivated the consideration of more flexible designs relaxing the
monotonicity assumption, namely, Partial Ordering Continual Reassessment
Method and No Monotonicity Assumption design that are unique in their
ability to handle partially ordered combinations that do not necessarily form a
grid of combinations. Both model-based and model-assisted designs based on
monotonicity assumption failed to identify the MTD consistently when this
assumption was violated. It was found that the ordering can have a large
impact on a phase I study and the monotonicity assumption should be
carefully justified during the planning of a phase I trial with a combination of
treatments. The designs relaxing the monotonicity assumption led to robust
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performances in all permutations of orderings. On average across all
considered scenarios, the No Monotonicity Assumption design selected less
often toxic doses than the Partial Ordering Continual Reassessment Method
but the Partial Ordering Continual Reassessment Method allocated on
average less patients to toxic doses.
The motivating trial assesses toxicity of a combination of a cytotoxic
chemotherapy with an immunotherapy. The assumption that higher dose
leads to higher efficacy and toxicity holds, but for dose levels 3, 4 and 5. Yet,
one may have interest in assessing both toxicity and efficacy as in Wages and
Tait33. In the setting of our motivating trial the proposed endpoint for
efficacy would have been response to treatment. This requires tumour
response evaluation after nearly 85 days of treatment, which was not feasible,
as efficacy outcomes couldn’t be obtained soon enough to make adaptive
decision for a new cohort given an accrual rate of 4 patients per month. The
problem of late onset outcome in early phase clinical trials was discussed by
Cheung and Chappell34, and later by Braun35 and Liu and Ning36. An
application can be found in Ick et al.37.
If a monotonic order cannot be specified, two alternatives, the Partial
Ordering Continual Reassessment Method and the No Monotonicity
Assumption design, should be considered. Regardless which design is chosen,
we advocate that the first (and essential) step is to restrict the number of
orderings in each particular setting. Wages et al.38 showed that the
25
performance of the Partial Ordering Continual Reassessment Method
decreases as the number of orderings increases. Also, it has been
demonstrated by Mozgunov and Jaki17 that No Monotonicity Assumption
design accuracy could also decrease if the number of potential dose-toxicity
relations for calibration is large.
The choice of the orderings should be made after an extensive discussion with
experts whatever the design. The first point to discuss is the validity of the
monotonicity assumption. Then we recommend that the choice of the design
should be guided by a comprehensive simulation study taking into account the
preference for each scenario. For instance, if an investigator believes that a
scenario with the MTD being the last dose is the most probable in a
non-monotonic relationship, the Partial Ordering Continual Reassessment
Method should be considered as a primary candidate. On the other hand, if a
scenario with the MTD located in the middle of the dose range about which
the monotonicity assumption can be violated, the No Monotonicity
Assumption design should be prioritized. The No Monotonicity Assumption
design should also be prioritized if interaction that can lead to large difference
in toxicity can occur as in non monotonic scenarios 7.2 and 9.2. Depending on
the scenario, small changes in the set of parameters used for the Continual
Reassessment Method and the Partial Ordering Continual Reassessment
Method can impact the operating characteristics of the design. As
investigators usually do not have data prior the trial to guess the most likely
scenario, simulations should be conducted with great care with respect to the
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choice of the initials parameters and the scenarios. Importantly, as stated by
Mozgunov and Jaki23 and shown above, relaxing of monotonicity assumption
might result in higher number of DLTs for both No Monotonicity Assumption
design and Partial Ordering Continual Reassessment Method. It can be
explained by the fact that they require to investigate more dose levels before
selecting the correct ordering. This cost of considering different orderings
should be taking into account when planning a study. The parameters of
safety constraints should be extensively discussed with the experts to avoid
the exposure of patients to excessively toxic dose levels.
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Table 1: Operating characteristics in scenarios 1-3.2: proportions of selections at each dose
level and respective average number of patients assigned (in brackets). The proportion of the
true MTD selection is in bold. The proportion of early stopping for safety is given in column
”Stop”, the probability of selecting toxic doses as the MTD in ”SelTox” and the percentage
of patients assigned to the toxic doses in ”%Tox”. Results are based on 104 replications.
CRM: Continual Reassessment Method; PO-CRM: Partial Ordering Continual Reassessment
Method; mTPI: modified Toxicity Probability Interval design; BOIN: Bayesian Optimal
Interval design; NMA: No Monotonicity Assumption design.
d1 d2 d3 d4 d5 d6 Stop SelTox %Tox
Scenario 1 0.30 0.40 0.50 0.60 0.90 0.90
Benchmark 76.4 20.5 0.3 0.1 0.0 0.0
CRM
48.5 25.7 3.9 0.2 0.0 0.0 21.7 29.7 52.3
(12.5) (10.4) (2.9) (0.4) (0.0) (0.0)
PO-CRM
49.3 25.0 3.6 1.6 0.0 0.0 20.4 30.3 53.6
(12.2) (10.1) (2.8) (1.2) (0.1) (0.0)
mTPI
65.4 9.9 5.1 0.2 0.0 0.0 19.5 15.2 63.3
(9.8) (13.7) (2.9) (0.3) (0.0) (0.0)
BOIN
40.7 29.1 5.1 0.3 0.0 0.0 24.9 34.4 60.6
(10.3) (12.0) (3.3) (0.4) (0.0) (0.0)
NMA
54.8 23.6 4.9 2.1 0.1 0.0 14.5 30.7 52.5
(13.4) (8.8) (2.3) (2.2) (1.5) (0.0)
Scenario 2 0.14 0.30 0.40 0.50 0.70 0.75
Benchmark 14.1 62.3 20.6 3.0 0.0 0.0
CRM
15.0 53.7 24.8 3.0 0.1 0.0 3.4 27.9 30.9
(6.1) (14.1) (7.1) (1.6) (0.2) (0.0)
PO-CRM
14.1 50.7 22.4 8.7 0.9 0.0 3.2 32.0 35.6
(5.7) (13.1) (6.8) (3.0) (0.5) (0.0)
mTPI
50.1 26.0 18.8 3.4 0.1 0.0 1.7 22.3 26.1
(6.8) (15.1) (6.2) (1.4) (0.1) (0.0)
BOIN
18.7 52.8 21.5 4.3 0.1 0.0 2.5 26.0 31.1
(5.6) (14.7) (7.1) (1.8) (0.2) (0.0)
NMA
26.1 41.1 18.7 11.0 2.7 0.0 0.4 32.4 41.5
(6.7) (10.9) (4.6) (4.7) (3.1) (0.1)
Scenario 3.1 0.05 0.10 0.20 0.30 0.45 0.70
Benchmark 0.0 1.4 27.9 55.7 15.1 0.0
CRM
0.0 2.4 27.6 52.8 16.9 0.2 0.1 17.1 16.1
(0.3) (5.4) (9.6) (9.8) (4.3) (0.6)
PO-CRM
0.0 2.4 33.9 40.7 22.4 0.7 0.0 23.0 19.1
(0.3) (5.0) (10.0) (9.0) (5.2) (0.6)
mTPI
2.7 12.4 33.0 38.4 13.1 0.4 0.0 13.5 12.0
(0.7) (7.0) (10.2) (8.5) (3.2) (0.4)
BOIN
0.3 4.4 29.9 47.0 17.8 0.5 0.0 18.4 15.6
(0.3) (5.8) (9.8) (9.4) (4.1) (0.5)
NMA
2.5 7.1 27.5 40.0 21.5 1.3 0.0 22.8 26.3
(1.7) (5.5) (6.3) (8.6) (6.7) (1.2)
Scenario 3.2 0.05 0.10 0.30 0.20 0.45 0.70
CRM
0.0 8.1 33.5 35.7 22.3 0.3 0.1 22.6 15.9
(0.5) (7.2) (10.7) (6.8) (4.3) (0.5)
PO-CRM
0.0 3.2 44.7 34.1 17.3 0.5 0.1 17.8 15.4
(0.4) (5.3) (11.6) (8.0) (4.1) (0.5)
mTPI
2.8 28.4 23.7 31.6 13.0 0.4 0.0 13.4 12.1
(0.7) (10.1) (9.3) (6.2) (3.3) (0.4)
BOIN
0.3 17.3 27.0 33.8 21.0 0.6 0.0 21.5 16.2
(0.3) (8.8) (9.6) (6.5) (4.3) (0.6)
NMA
2.7 7.6 38.5 32.0 17.5 1.7 0.0 19.2 25.3
(2.0) (5.9) (7.4) (7.1) (6.3) (1.3)
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Table 2: Operating characteristics in scenarios 3.3-6: proportions of selections at each dose
level and respective average number of patients assigned (in brackets). The proportion of the
true MTD selection is in bold. The proportion of early stopping for safety is given in column
”Stop”, the probability of selecting toxic doses as the MTD in ”SelTox” and the percentage
of patients assigned to the toxic doses in ”%Tox”. Results are based on 104 replications.
CRM: Continual Reassessment Method; PO-CRM: Partial Ordering Continual Reassessment
Method; mTPI: modified Toxicity Probability Interval design; BOIN: Bayesian Optimal
Interval design; NMA: No Monotonicity Assumption design.
d1 d2 d3 d4 d5 d6 Stop SelTox %Tox
Scenario 3.3 0.05 0.10 0.20 0.45 0.30 0.70
CRM
0.0 3.0 47.9 34.0 13.5 1.4 0.1 35.4 29.2
(0.3) (5.6) (12.1) (8.1) (3.1) (0.7)
PO-CRM
0.0 3.3 32.4 27.8 35.6 0.9 0.1 28.6 28.4
(0.3) (5.3) (10.0) (8.0) (5.8) (0.5)
mTPI
2.7 12.5 59.0 14.0 11.4 0.4 0.0 14.4 20.8
(0.7) (7.0) (14.1) (5.9) (2.0) (0.4)
BOIN
0.3 4.5 59.4 20.6 14.5 0.7 0.0 21.3 26.6
(0.3) (5.9) (13.6) (7.4) (2.3) (0.6)
NMA
2.7 8.0 24.2 23.7 40.2 1.2 0.0 24.9 30.9
(1.6) (5.5) (5.9) (7.6) (7.8) (1.7)
Scenario 4 0.01 0.05 0.10 0.15 0.20 0.30
Benchmark 0.0 0.0 0.8 6.5 24.0 68.8
CRM
0.0 0.0 1.2 10.4 35.2 53.2 0.0 0.0 0.0
(0.1) (3.7) (4.7) (5.8) (7.4) (8.4)
PO-CRM
0.0 0.0 2.8 15.2 27.6 54.4 0.0 0.0 0.0
(0.1) (3.5) (5.0) (6.5) (6.6) (8.4)
mTPI
0.7 2.9 7.6 16.9 29.6 42.3 0.0 0.0 0.0
(0.2) (4.3) (5.6) (6.6) (6.6) (6.7)
BOIN
0.1 0.3 2.2 11.0 30.6 55.8 0.0 0.0 0.0
(0.0) (3.7) (4.9) (6.2) (7.0) (8.1)
NMA
0.1 1.0 7.5 17.4 23.5 50.5 0.0 0.0 0.0
(0.5) (4.0) (3.8) (6.2) (7.3) (8.2)
Scenario 5 0.001 0.01 0.05 0.07 0.10 0.15
Benchmark 0.8 0.3 3.2 4.0 13.6 78.2
CRM
0.0 0.0 0.0 0.3 4.6 95.0 0.0 0.0 0.0
(0.0) (3.1) (3.5) (3.5) (4.5) (15.4)
PO-CRM
0.0 0.0 0.1 1.1 3.3 95.4 0.0 0.0 0.0
(0.0) (3.1) (3.6) (4.1) (4.1) (15.2)
mTPI
0.0 0.8 1.5 3.6 9.2 84.9 0.0 0.0 0.0
(0.0) (3.3) (3.8) (4.3) (5.0) (13.6)
BOIN
0.0 0.0 0.1 0.8 4.5 94.6 0.0 0.0 0.0
(0.0) (3.1) (3.6) (4.0) (4.7) (14.6)
NMA
0.0 0.0 1.5 3.4 7.0 88.1 0.0 0.0 0.0
(0.3) (3.3) (2.3) (4.4) (5.5) (14.2)
Scenario 6 0.50 0.70 0.80 0.90 0.95 0.95
Benchmark 99.9 0.1 0.00 0.00 0.00 0.00
CRM
7.0 0.0 0.0 0.0 0.0 0.0 93.0 7.0 100.0
(7.6) (3.9) (0.1) (0.0) (0.0) (0.0)
PO-CRM
7.5 0.1 0.0 0.0 0.0 0.0 92.4 7.6 100.0
(7.7) (3.9) (0.1) (0.0) (0.0) (0.0)
mTPI
9.9 0.0 0.0 0.0 0.0 0.0 90.1 9.9 100.0
(9.2) (4.4) (0.1) (0.0) (0.0) (0.0)
BOIN
9.4 0.0 0.0 0.0 0 0.0 90.6 9.4 100.0
(9.1) (4.3) (0.1) (0.0) (0.0) (0.0)
NMA
13.1 0.2 0.0 0.0 0.0 0.0 86.7 13.3 100.0
(10.5) (2.9) (0.1) (0.1) (0.1) (0.0)
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Table 3: Operating characteristics in scenarios 7-8.2: proportions of selections at each dose
level and respective average number of patients assigned (in brackets). The proportion of
correct MTD selection is in bold. The proportion of early stopping for safety is given in
column ”Stop”, the probability of selecting toxic doses as the MTD in ”SelTox” and the
percentage of patients assigned to the toxic doses in ”%Tox”. Results are based on 104
replications. CRM: Continual Reassessment Method; PO-CRM: Partial Ordering Continual
Reassessment Method; mTPI: modified Toxicity Probability Interval design; BOIN: Bayesian
Optimal Interval design; NMA: No Monotonicity Assumption design.
d1 d2 d3 d4 d5 d6 Stop SelTox %Tox
Scenario 7.1 0.01 0.05 0.20 0.50 0.60 0.70
Benchmark 0.0 0.2 77.8 21.6 0.4 0.0
CRM
0.0 2.1 61.9 35.0 1.0 0.0 0.0 36.0 35.6
(0.1) (4.8) (14.4) (9.1) (1.5) (0.1)
PO-CRM
0.0 2.6 58.2 26.7 12.4 0.0 0.0 39.1 39.4
(0.1) (4.8) (13.3) (8.0) (3.7) (0.1)
mTPI
0.7 11.9 71.4 15.0 1.1 0.0 0.0 16.1 24.0
(0.2) (6.2) (16.4) (6.4) (0.8) (0.0)
BOIN
0.1 3.9 73.1 21.6 1.3 0.0 0.0 22.9 29.9
(0.0) (5.1) (15.9) (8.0) (0.9) (0.1)
NMA
0.7 4.8 52.9 23.9 17.2 0.4 0.0 41.5 48.0
(1.9) (5.5) (8.2) (8.6) (5.5) (0.3)
Scenario 7.2 0.01 0.05 0.50 0.20 0.60 0.70
CRM
0.0 33.2 47.5 14.3 5.0 0.0 0.0 52.5 49.5
(0.8) (11.4) (13.5) (2.9) (1.3) (0.1)
PO-CRM
0.0 7.2 35.8 55.4 1.6 0.0 0.0 37.4 43.0
(0.4) (6.3) (11.7) (10.4) (1.1) (0.1)
mTPI
0.7 76.1 8.2 14.0 1.0 0.0 0.0 9.2 26.8
(0.2) (19.1) (7.3) (2.7) (0.7) (0.0)
BOIN
0.1 63.9 19.2 14.7 2.1 0.1 0.0 21.3 34.5
(0.0) (17.0) (9.2) (2.6) (1.1) (0.1)
NMA
0.6 3.5 25.9 65.0 3.9 1.0 0.0 30.9 43.5
(2.5) (6.2) (8.0) (8.3) (4.5) (0.6)
Scenario 8.1 0.01 0.05 0.10 0.25 0.45 0.60
Benchmark 0.0 0.0 2.8 72.8 24.1 0.3
CRM
0.0 0.0 6.8 61.0 30.6 1.4 0.0 32.1 28.5
(0.1) (3.7) (6.0) (11.7) (7.2) (1.4)
PO-CRM
0.0 0.0 17.7 47.6 32.8 1.9 0.0 34.7 29.6
(0.1) (3.6) (7.1) (10.3) (7.5) (1.4)
mTPI
0.7 2.9 19.7 55.2 20.1 1.4 0.0 21.5 20.1
(0.2) (4.3) (7.7) (11.9) (5.3) (0.8)
BOIN
0.1 0.3 10.1 61.1 26.4 2.0 0.0 28.4 24.6
(0.0) (3.7) (6.7) (12.1) (6.3) (1.0)
NMA
0.5 2.4 20.3 46.5 25.9 4.3 0.0 30.2 31.6
(1.3) (4.8) (5.1) (9.4) (7.6) (1.9)
Scenario 8.2 0.01 0.05 0.25 0.10 0.45 0.60
CRM
0.0 1.8 16.2 36.6 43.9 1.4 0.0 45.4 28.8
(0.1) (5.0) (8.6) (7.6) (7.4) (1.2)
PO-CRM
0.0 0.2 44.2 22.0 31.5 2.0 0.0 33.6 26.1
(0.1) (3.8) (11.3) (7.0) (6.5) (1.3)
mTPI
0.7 19.2 18.2 40.1 20.3 1.6 0.0 21.9 19.9
(0.2) (7.8) (8.5) (7.6) (5.2) (0.8)
BOIN
0.1 7.9 17.4 38.9 33.6 2.1 0.0 35.7 25.4
(0.0) (6.3) (8.3) (7.8) (6.6) (1.0)
NMA
0.6 2.1 48.0 21.0 23.8 4.5 0.0 28.2 31.3
(1.5) (5.1) (8.3) (5.7) (7.3) (2.1)
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Table 4: Operating characteristics in scenarios 8.3-9: proportions of selections at each dose
level and respective average number of patients assigned (in brackets). The proportion of
correct MTD selection is in bold. The proportion of early stopping for safety is given in
column ”Stop”, the probability of selecting toxic doses as the MTD in ”SelTox” and the
percentage of patients assigned to the toxic doses in ”%Tox”. Results are based on 104
replications. CRM: Continual Reassessment Method; PO-CRM: Partial Ordering Continual
Reassessment Method; mTPI: modified Toxicity Probability Interval design; BOIN: Bayesian
Optimal Interval design; NMA: No Monotonicity Assumption design.
d1 d2 d3 d4 d5 d6 Stop SelTox %.Tox
Scenario 8.3 0.01 0.05 0.10 0.45 0.25 0.60
CRM
0.0 0.1 28.5 43.1 22.4 5.9 0.0 49.0 39.2
(0.1) (3.8) (9.4) (10.1) (4.9) (1.7)
PO-CRM
0.0 0.1 11.9 35.1 50.3 2.5 0.0 37.6 36.8
(0.1) (3.7) (7.0) (9.9) (8.2) (1.2)
mTPI
0.7 2.9 62.6 15.9 16.4 1.5 0.0 17.3 27.7
(0.2) (4.3) (14.5) (7.6) (2.8) (0.8)
BOIN
0.1 0.3 51.8 26.7 18.1 3.0 0.0 29.7 33.9
(0.0) (3.7) (13.2) (9.0) (2.8) (1.2)
NMA
0.5 2.8 10.0 28.7 53.9 4.1 0.0 32.9 37.3
(1.1) (4.6) (4.5) (8.6) (8.6) (2.6)
Scenario 9.1 0.01 0.05 0.08 0.10 0.25 0.45
Benchmark 0.0 0.0 0.5 2.3 73.0 24.2
CRM
0.0 0.0 0.3 9.6 60.5 29.5 0.0 29.5 21.4
(0.1) (3.6) (4.2) (5.5) (10.2) (6.4)
PO-CRM
0.0 0.0 3.8 15.8 49.8 30.6 0.0 30.6 22.3
(0.1) (3.5) (4.8) (6.1) (8.8) (6.7)
mTPI
0.7 1.9 3.7 20.6 52.2 20.9 0.0 20.9 16.1
(0.2) (4.0) (4.6) (6.8) (9.6) (4.8)
BOIN
0.1 0.2 0.7 11.1 60.8 27.2 0.0 27.2 19.7
(0.0) (3.7) (4.1) (6.2) (10.1) (5.9)
NMA
0.2 1.5 9.0 22.9 40.1 26.4 0.0 26.4 20.4
(0.7) (4.2) (4.2) (5.7) (9.0) (6.1)
Scenario 9.2 0.01 0.05 0.08 0.25 0.10 0.45
CRM
0.0 0.0 3.0 18.1 36.3 42.6 0.0 42.6 24.3
(0.1) (3.6) (5.0) (6.9) (7.2) (7.3)
PO-CRM
0.0 0.0 1.2 41.7 24.5 32.6 0.0 32.6 20.9
(0.0) (3.5) (4.5) (9.6) (6.0) (6.3)
mTPI
0.7 1.9 18.7 18.2 38.3 22.1 0.0 22.1 16.3
(0.2) (4.0) (7.3) (7.4) (6.2) (4.9)
BOIN
0.1 0.2 8.5 19.6 37.6 34.0 0.0 34.0 20.3
(0.0) (3.7) (6.2) (7.7) (6.3) (6.1)
NMA
0.2 1.3 5.3 48.6 16.3 28.3 0.0 28.3 21.3
(0.6) (4.1) (3.9) (9.1) (5.9) (6.4)
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